Recursion Pharmaceuticals (RXRX) Income from Continuing Operations (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Income from Continuing Operations came in at 117504000.0 in Q1 2026, up 41.97% YoY from 82767010.29 in Q1 2025, and down 8.68% on a QoQ basis from 108122000.0 in Q4 2025.
Recursion Pharmaceuticals (RXRX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Income from Continuing Operations data on file, last reported at 117504000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 41.97% year-over-year to 117504000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 559776000.0 (up 2.61% YoY) and the FY2025 annual result came in at 644759000.0, down 39.06% from the prior year.
- Income from Continuing Operations retreated to 117504000.0 in Q1 2026, from 108122000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 55995000.0 in Q1 2022 to a low of 202487000.0 in Q1 2025.
- A 5-year average of 106283882.35 and a median of 93017000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations slumped 121.6% — and 2026, when it soared 41.97%.
- Tracing RXRX's Income from Continuing Operations over 5 years: stood at 68050000.0 in 2022, then tumbled by 36.66% to 92996000.0 in 2023, then tumbled by 92.38% to 178906000.0 in 2024, then jumped by 39.56% to 108122000.0 in 2025, then slipped by 8.68% to 117504000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 117504000.0 (Q1 2026), 108122000.0 (Q4 2025), and 162253000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | -131.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -131.01 Mn |
| Mar 31, 2026 | -117.50 Mn |
| Dec 31, 2025 | -108.12 Mn |
| Sep 30, 2025 | -162.25 Mn |
| Jun 30, 2025 | -171.90 Mn |
| Mar 31, 2025 | -202.49 Mn |
| Dec 31, 2024 | -178.91 Mn |
| Sep 30, 2024 | -95.84 Mn |
| Jun 30, 2024 | -97.54 Mn |
| Mar 31, 2024 | -91.37 Mn |
| Dec 31, 2023 | -93.00 Mn |
| Sep 30, 2023 | -93.02 Mn |
| Jun 30, 2023 | -76.73 Mn |
| Mar 31, 2023 | -65.33 Mn |
| Dec 31, 2022 | -68.05 Mn |
| Sep 30, 2022 | -62.59 Mn |
| Jun 30, 2022 | -66.21 Mn |
| Mar 31, 2022 | -56.00 Mn |
| Dec 31, 2021 | -64.98 Mn |
| Sep 30, 2021 | -46.62 Mn |